Fresh Recalls

FDAClass III · Drug · Recall D-0735-2026 · Recalled July 29, 2026

Dabigatran etexilate Capsules recall — Ascend Laboratories, LLC

Agency report date: July 29, 2026.

1. Compare your item

This notice names a product; your particular item is not yet verified. Compare every applicable model, serial, lot, production-date or model-year boundary below.

Product named
Dabigatran etexilate Capsules
Company / brand
Ascend Laboratories
Lot / serial / date codes
Lot: 25141707, Exp 4/30/2027.
Distribution
USA Nationwide
Agency product description and boundaries

Dabigatran etexilate Capsules, 110 mg, 60-count carton (6x10), Rx Only, Manufactured by: Alkem Laboratories, Mumbai, INDIA, Distributed by: Major Pharmaceuticals, Indianapolis, IN 46268, NDC 0904-7254-68.

Still to verify: match the label on your item with the full official notice, including any exclusions, tables and photos. Some identifiers appear only on the agency website and are absent from this data feed. A missing field does not mean all versions are affected.

If your lot or date falls outside a stated range, this notice has not established that your item is affected. This is not a finding about other recalls or product safety.

2. Agency hazard and consumer action

FDA reports: Failed Impurities/Degradation Specifications: OOS result was observed during the related substance test analysis with respect to Impurity II, Impurity III and Total impurity testing for 12 Month Long-Term Stability.

No consumer remedy instructions are supplied in this record. Check the official notice and listed company contact for the agency’s current instructions.

Class III: not likely to cause adverse health consequences.

Affected product: Dabigatran etexilate Capsules

3. Open the official notice or contact

Official recall ID
D-0735-2026
Brand
Ascend Laboratories
Classification
Class III
Units affected
1,753 cartons
Recall status
Ongoing
Initiated
Voluntary: Firm initiated

Affected products

Companies & origin

Recalling firm location
Bedminster, NJ, United States
Firm address
135 Us Highway 202 206 Ste 15, N/A, 07921-2608

Identifying details (verbatim from the notice)

Product codes / lots
Lot: 25141707, Exp 4/30/2027.
Distribution
USA Nationwide
Firm notified the public via
Letter
FDA event ID
99330
Recall initiated
June 30, 2026
FDA classified
August 4, 2026
FDA report date
July 29, 2026
Verify with the official sources:

Found something wrong or missing? Report a data error.

Source: U.S. Food & Drug Administration. Agency excerpts come from the public data feed and may omit tables or later changes; the linked government source is authoritative. Source last checked September 7, 2026 at 6:00 AM UTC. Record retrieved September 7, 2026 at 6:00 AM UTC.

Report a data error on this page